Cargando…
Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs
BACKGROUND: Novel agents (NAs) (ibrutinib, idelalisib, and venetoclax) were first introduced in 2013 as therapeutic options to treat chronic lymphocytic leukemia (CLL). OBJECTIVES: To determine if the uptake of NAs for first-line treatment was similar in Black and White patients with CLL treated in...
Autores principales: | Lucero, Kana Tai, Obodozie-Ofoegbu, Obiageri O, Nooruddin, Zohra, Ryan, Kellie, Castillo, Alyssa, Moore, Amanda M, Jones, Xavier, Frei, Christopher R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387978/ https://www.ncbi.nlm.nih.gov/pubmed/36989449 http://dx.doi.org/10.18553/jmcp.2023.29.4.420 |
Ejemplares similares
-
1881. Empiric Pseudomonal Monotherapy vs. Combination Therapy for Community-Onset Pneumonia in Older Adults
por: Obodozie-Ofoegbu, Obiageri, et al.
Publicado: (2018) -
Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019) -
Disparities in Excess, All-Cause Mortality among Black, Hispanic, and White Veterans at the U.S. Department of Veterans Affairs during the COVID-19 Pandemic
por: Lukowsky, Lilia R., et al.
Publicado: (2022) -
2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018) -
Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)